Yubin Miao

Prof. Yubin Miao


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JYJianquan Yang
Jianquan Yang
JXJingli Xu
Jingli Xu
RGRene Gonzalez
Rene Gonzalez
TLThomas Lindner
Thomas Lindner
CKClemens Kratochwil
Clemens Kratochwil
YMYubin Miao
Yubin Miao
68 Ga-DOTA-GGNle-CycMSH hex , a radiolabeled melanocortin-1 receptor–targeting imaging probe, detects melanoma in first-in-human testing.

14 February 2019 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
JYJianquan Yang
Jianquan Yang
JXJingli Xu
Jingli Xu
LCLina Cheuy
Lina Cheuy
RGRene Gonzalez
Rene Gonzalez
DFDarrell R. Fisher
Darrell R. Fisher
YMYubin Miao
Yubin Miao

4 December 2020 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
YMYubin Miao
Yubin Miao
TQThomas P. Quinn
Thomas P. Quinn
Melanocortin-1 receptor (MC1R) and very late antigen-4 (VLA-4, integrin α4β1) are 2 attractive molecular targets for developing peptide radiopharmaceuticals for melanoma imaging and therapy. MC1R- and VLA-4–targeting peptides and peptide-conjugated Cornell prime dots (C′ dots) can serve as delivery vehicles to target both diagnostic and therapeutic radionuclides to melanoma cells for imaging and therapy. This review highlights the advances of MC1R- and VLA-4–targeted radiolabeled peptides and peptide-conjugated C′ dots for melanoma imaging and therapy. The promising preclinical and clinical results of these new peptide radiopharmaceuticals present an optimistic outlook for clinical translation into receptor-targeting melanoma imaging and radionuclide therapy in the future.

28 July 2020 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
ZQZheng Qiao
Zheng Qiao
JXJingli Xu
Jingli Xu
RGRene Gonzalez
Rene Gonzalez
YMYubin Miao
Yubin Miao

1 November 2019 in Cancer Biotherapy and Radiopharmaceuticals
Verified
Journal Article
Closed access
JXJingli Xu
Jingli Xu
JYJianquan Yang
Jianquan Yang
RGRene Gonzalez
Rene Gonzalez
DFDarrell R. Fisher
Darrell R. Fisher
YMYubin Miao
Yubin Miao
Purpose: The purpose of this study was to evaluate melanoma-targeting property of 90Y-DOTA-GGNle-CycMSHhex to facilitate its potential therapeutic application. Materials and Methods: DOTA-GGNle-CycMSHhex was synthesized and readily labeled with 90Y in 0.25 M NH4Ac-buffered solution to generate 90Y-DOTA-GGNle-CycMSHhex. The specific receptor binding, internalization, and efflux of 90Y-DOTA-GGNle-CycMSHhex were determined on B16/F10 murine melanoma cells. The biodistribution property of 90Y-DOTA-GGNle-CycMSHhex was examined on B16/F10 melanoma-bearing C57 mice. Results:90Y-DOTA-GGNle-CycMSHhex displayed receptor-specific binding, rapid internalization, and prolonged efflux on B16/F10 melanoma cells. 90Y-DOTA-GGNle-CycMSHhex exhibited high uptake and prolonged retention in melanoma, and fast urinary clearance on B16/F10 melanoma-bearing C57 mice. The B16/F10 tumor uptake was 20.73% ± 7.99%, 19.93% ± 5.73%, 14.8% ± 4.61%, and 6.69% ± 1.85% ID/g at 0.5, 2, 4, and 24 h postinjection, respectively. Conclusions:90Y-DOTA-GGNle-CycMSHhex displayed melanocortin-1 receptor (MC1R) targeting and specificity on B16/F10 melanoma cells and tumors. The favorable melanoma-targeting property and fast urinary clearance of 90Y-DOTA-GGNle-CycMSHhex warranted its evaluation for melanoma therapy in future studies.

29 April 2022 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
ZQZheng Qiao
Zheng Qiao
JXJingli Xu
Jingli Xu
RGRene Gonzalez
Rene Gonzalez
YMYubin Miao
Yubin Miao